The GOLD (Global Oncologic Learnings for Dovitinib) Trials are a series of global initiatives led by Novartis that encompass a broad range of malignancies, breast cancer, gastric cancer, and hepatocellular carcinoma (HCC). Through this program Novartis is conducting clinical studies of dovitinib (TKI258) as a single agent and in combination with other agents.1
Novartis clinical trials that are recruiting subjects in countries outside of the United States are posted on ClinicalTrials.gov, which is a Web site service provided by the U.S. National Institutes of Health (NIH). The NIH, through its National Library of Medicine (NLM), has developed this Web site in collaboration with the Food and Drug Administration (FDA), as a result of the FDA Modernization Act, which was passed into law in November 1997.
Search ClinicalTrials.gov for information about other clinical trials seeking patient participation.